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Abstract
Epigenetics is the study of heritable traits that are not caused by alterations to
DNA. An example of such a mechanism is histone methylation, specifically
histone H3 lysine 4 (H3K4). Histones are proteins that wrap and package DNA
into nucleosomes. Modifications to a histone’s chemistry can up or down regulate
specific gene expression programs through changes in nucleosome positioning.
Human mixed lineage leukemia protein-1 (MLL1) is a member of the SET1
family of H3K4 methyltransferases. Previous studies in the Cosgrove lab have
shown that an interaction between two protein sub-complexes, MLL1 and WRAD
(WDR5, RbBP5, Ash2L, DPY30), leads to dimethylation. H3K4 dimethylation
plays an important role in normal development and hematopoiesis in humans.
Disruption of core complex formation from amino acid point mutations can lead
to a decrease, or even complete loss, of dimethylation.
Kabuki Syndrome (KS) is a multiple malformation disorder that was recently
discovered to be associated with mutations in mixed lineage leukemia protein-2
(MLL2), a paralog of MLL1 and member of the SET1 family of proteins. Using
the experimental model established with MLL1, tests were conducted that
determined the importance of a highly conserved arginine residue (R). In MLL1,
this R3765 (MLL2 R5340) was mutated into leucine, which revealed a severe loss
of H3K4 dimethylation resulting from failure of MLL1 to interact with WDR5.
Additional KS and non-KS (control) MLL1 mutations from MLL2 screens of
patients were tested and suggested a correlation between changes in H3K4
methylation and KS.
Protein arginine deiminases (PADs) are enzymes that post translationally modify
arginine into citrulline, a non-standard amino acid. Previous work with KS led us
to hypothesize a possible regulation system of PAD and SET1 family proteins.
While PAD is able to disrupt complex formation by changing R3765 into
citrulline, thereby down-regulating dimethylation, mutations in SET1 family
proteins can elevate dimethylation when in complex with WRAD. Thereby
creating an “on” and “off” system of protein interaction. Previous work in the
Cosgrove lab showed preferential interaction between PAD2 and MLL1. Initial
assays were conducted and optimized that supported this hypothesis, as well as
laying the ground work for future experimentation.
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Executive Summary
Mixed lineage leukemia protein-1 (MLL1) and WRAD (WDR5, RbBP5, Ash2L,
DPY30) are two parts of a protein core complex called MWRAD. Separately,
MLL1 and WRAD can only monomethylate, which means they add one methyl
(CH3) group onto a histone called histone H3 lysine 4 (H3K4). When in complex,
MWRAD is able to dimethylate or add two methyl groups. Histones are proteins
that consolidate DNA by wrapping them up. Without histones the DNA would be
very long and each human cell would contain 1.8 meters of DNA, as opposed to
90 micrometers, a ten-thousand fold difference. Usually genes and traits are
thought to be passed down through each individual’s genetic DNA code.
However, there exists a new field of study called epigenetics, whereby inherited
traits are passed down through modifications outside of DNA, an example being
histone methylation.
The Cosgrove lab has worked extensively with this model system and have
discovered a highly conserved six amino acid motif in MLL1 called the Win
motif that acts as a bridge with WDR5. Mutations in this region lead to a
disruption of complex formation between MLL1 and WRAD, thereby decreasing
the amount of H3K4 dimethylation. This can be thought as a lock and key
mechanism where the Win motif is inserted into a WRAD binding site.
My work has primarily revolved around that region of MLL1 and understanding
the mechanisms behind the regulation of this MLL1 core complex. During my
three years, I was tasked with two separate projects. The first focused on Kabuki
Syndrome (KS), a congenital disorder that has been linked with MLL2. MLL1
and MLL2 are part of a family of proteins, so they are very similar in nature.
Therefore, it was hypothesized that we could test KS and non-KS (controls)
mutations found in MLL2 using MLL1. Results showed a correlation between
mutations in KS patients and a loss of dimethylation.
After successfully publishing a paper with members of the Cosgrove lab, I was
assigned to a second project dealing with protein arginine deiminase (PAD), an
enzyme that modifies an amino acid called arginine. Prior work showed a relation
between PAD2 and MLL1 leading us to believe that there could exist a regulation
mechanism for H3K4 dimethylation. Essentially PAD2 would hypothetically
lower dimethylation in the case that there is an overexpression of dimethylation,
as the human body maintains a delicate homeostasis by keeping gene expression
in a specific range. Furthermore, detrimental mutations to PAD2 could be a cause
for KS, as it would change one of the highly conserved amino acids in the Win
motif. Unfortunately I was only able to lay the ground works for this project due
to time constraints. Future work will hopefully be able to verify the data that was
obtained.
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Chapter I
Introduction

The Human Mixed Lineage Leukemia Protein-1 (MLL1) Core Complex
Nucleosomes are fundamental units in genetic regulation and they consist of DNA
wrapped around eight histone proteins. Changes in the position of a nucleosome
can cause varying levels of over-expression or suppression of genes. Chromatin,
containing multiple nucleosomes, can be transcriptionally activated or deactivated
with histone lysine methylation, a crucial epigenetic system1. Epigenetics is the
study of gene expression programs that does not originate from alterations in the
DNA. Post-translational modifications of histones can reveal or cover binding
sites for proteins involved in gene expression. Mixed lineage leukemia protein -1,
MLL1, named as such due to mutations frequently leading to acute leukemia, is
one of six members in the SET1 family of H3K4 methyltransferases with the
other five being: MLL2, MLL3, MLL4, SET1a, and SET1b1. The SET1 family is
one of many SET domain proteins that exist based on similarities in sequence and
structural features. Alone, the SET1 family can only participate in the slow
monomethylation of H3K41. However, dimethylation is possible in the presence
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of the WDR5, RbBP5, ASH2L, and DPY-30 (WRAD) complex1. WRAD acts
similarly to MLL1 and can monomethylate H3K41. MWRAD, in contrast, shows
a ~600 fold increase in H3K4 dimethylation1. Interestingly, mono- and
dimethylation occur sequentially at two unique sites in the MWRAD complex1.
Previous and current work in Dr. Michael Cosgrove’s lab focuses on
understanding the structure and function of MWRAD. H3K4 dimethylation is
important in the normal development and hematopoiesis of humans1. Under wildtype conditions, the MLL1 core complex is capable of H3K4 dimethylation, but
point mutations in the amino acid sequence altering the amount of dimethylation
have been linked with a variety of human diseases1. If the core complex is unable
to form, then there will only be monomethylation1.
Post Translational Modifications in Kabuki Syndrome
Kabuki Syndrome (OMIM 147920) is a human multiple malformation disorder
categorized by intellectual disability, facial abnormalities, heart problems, hearing
loss, growth deficiency, and short stature2. Due to the rare nature of this disease (1
in 32,000 with only 400 reported cases), it was not until 1981 that two separate
scientists, Norio Niikawa and Yoshikazu Kuroki, identified Kabuki Syndrome
(KS)2. Named as such due to the similarities with Kabuki makeup, a type of
Japanese theatre2. Since most reported incidences arose de novo, KS is suggested
to be an autosomal dominant disorder or X-linked recessive2. Classification of KS
is still not completely understood, as many of the conditions are shared with other
diseases like Down Syndrome2. Currently, four of the five cardinal features must
be met in order to make a KS diagnosis, including: facial appearance, skeletal
3

abnormalities, fetal finger pads, intellectual disability, and short stature3. Exome
sequencing in the early-2000s, as well as large spectrum analysis of KS patients
that followed were unable to pinpoint one shared gene at fault, however the
majority of individuals tested had a mutation in MLL22,3. Nine of ten patients in
the initial screen had an altered MLL2 gene, while two thirds of a larger (n = 43)
screen had mutations in MLL22. Seventy two percent of a 110 KS family screen
had adversely affected MLL23. Though not all those diagnosed with KS had the
MLL2 mutant, a possible explanation for those without MLL2 mutations could be
incorrect identification, the existence of another related developmental disease, or
mutations existing in the noncoding region2. Loss-of-function mutations in MLL2
likely alters H3K4 methylation in KS and, as such, is believed to be linked to the
problems in early human development for Kabuki Syndrome patients2. In
addition, tests done on MLL2 knock out mouse models were lethal3. KS is one of
many syndromes classified by developmental delay and disrupted histone
methylation3.
Significance of the WDR5 Interaction (Win) Motif
The WD repeat protein-5 (WDR5) is a conserved component in SET1 family
complexes that is shared across many different species4. It was discovered in 2008
that there exists a bridge between MLL1 and WDR5 that assists in core complex
formation4. The Win motif, a six amino acid residue sequence (GSARAE) is
located in the N-SET region of MLL1 and contains a highly conserved arginine
(R3765) that was shown to be bind in the pocket of WDR54. R3765 exists in all
members of the SET1 family and is important in the enzymatic activity of the
4

MWRAD complex5. Mutations in the Win motif could lead to a significant
disruption in the dimethylation activity attributed to normal hematopoiesis and
human growth6.
Mutations Affecting Histone H3 Lysine 4 (H3K4) Methylation
During the KS mutation screen, MLL2 arginine 5340 was found to be mutated
into a leucine2. This amino acid position is homologous to MLL1 R3765 in the
Win motif4. Due to the correlation between two previous research papers, it was
hypothesized that by utilizing the established in vitro model system of MLL1, the
effects of a mutation in MLL2 could be determined given the great amount of
similarity between the two proteins. MLL1 is a paralog of MLL2, thereby
presenting the opportunity to understand the effects of the KS MLL2 R5340
mutationL. This change in amino acid to leucine leads to a loss of charge, shorter
atomic structure, and increased hydrophobicity. In addition, a non-KS related
residue R3746 was mutated into a histidine as a control mutation that should not
impact H3K4 methylation. Other screened MLL2 mutations were tested by a
graduate student in the research lab. The identification and understanding of
Kabuki Syndrome point mutations will hopefully open doors for possible
treatments or earlier diagnosis7.
Peptidylarginine Deiminase (PAD) and the Impact of Citrullination
PAD enzymes catalyze the citrullination of arginine and have been implicated in
diseases such as rheumatoid arthritis, breast cancer, and multiple sclerosis8. The
conversion of the NH2+ group on arginine to a keto group on citrulline leads to a
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loss of the positive charge. The mammalian PAD family of enzymes consist of
PAD1, PAD2, PAD3, and PAD48. Of the four, PAD2 is expressed in the skeletal
muscle, brain, spleen, and secretory glands8. In order for these enzymes to
function properly, they require calcium ions (Ca2+)8. It has been hypothesized that
PAD could be used as a possible inhibitor to histone methyltransferases9. For
example, while MLL1 and WRAD interaction leads to dimethylation, PAD could
possibly disrupt the interaction if there was an overexpression of dimethylation. In
this way, citrullination can be used to counter a gain-of-function genetic mutation.
Given that histone methylation is an epigenetic modification that has been linked
with cancer, enzymes that directly or indirectly inhibit methylation could act as
drugs to counter uncontrolled cell growth9. Furthermore, this field of study has
only just begun to scratch the surface, if an inhibitor with specificity towards a
histone methyltransferase were created, then it could aid in the fight against
cancer, as well as other diseases9. In the past, the belief was that histone
methylation was a permanent genetic modification10. Prior work with MLL1
R3765 indicated that a mutation on this amino acid could lead to a complete loss
of dimethylation. It is hypothesized that an overexpression of PAD2 on this
arginine could lead to a patient with Kabuki Syndrome. It was shown in previous
experiments that PAD2 catalyzes citrullination of R3765 and R3771 in MLL1.
While based on previous work, citrullination of R3765 will likely disrupt complex
formation, it is unclear what functional consequences result from R3771
citrullination.
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Research Project Overview
The goal of work in my thesis was to understand how MLL1 core complex (Fig.
1) formation is regulated by R3765 and R3771 in MLL1.

Figure 1
In order to better understand the impact of MLL1 missense mutations, an
experimental model (Fig. 2) was used to compare complex formation and H3K4
methylation with wild-type MLL1.

Figure 2
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Chapter II
Materials and Methods

Mutagenesis. Point mutations were made using a site directed mutagenesis
kit (QuickChange II, Strategene) on truncated wild-type human MLL1
containing amino acid residues 3745-3969 in a pGST vector to introduce
R3746H, R3765L, and R3771T mutations. Plasmids were sequenced by
the DNA Sequencing Core Facility at SUNY Upstate Medical University
to verify the presence of the desired mutation and the absence of
additional unintended mutations. Primers were purchased from Integrated
DNA Technologies.

Protein Expression/Purification. Wild-type and mutant MLL1, as well as
full-length wild-type human WDR5, RbBP5, ASH2L, and DPY-30 were
individually expressed in Escherichia coli (Rosetta II, Novagen) and
purified using affinity chromatography, as previously described4. In
addition, proteins were dialyzed for buffer exchange and further purified
using a gel filtration column (Superdex, 200, GE Healthcare) with filtered
20mM Tris (pH 7.5), 300mM NaCl, 1mM Tris(2-carboxyethyl)phosphine,
8

and 1µM ZnCl2. Fractions from each step were selectively chosen after
using SDS-PAGE gels to confirm the protein by molecular weight and
maximize purity. Lastly, purified proteins were concentrated, if necessary,
using a centrifuge concentration tubes (Millipore, Minicon).

SDS-PAGE. Polyacrylamide gel electrophoresis (PAGE) was utilized to
determine concentrations and purity of protein samples, as well as
separating experimental time course reactions into individual protein
components. Sodium dodecyl sulfate (SDS), a detergent, denatures
proteins by unfolding them to become linear, thereby assisting in sample
analysis. Bands on the gel (BioRad, Mini Protein TGX) were compared to
a Precision Plus Protein Standard (BioRad). Coomassie stained and
destained images were captured using a Gel Doc (BioRad) and bands were
quantified using Image Lab.

Nanodrop Spectroscopy. Concentrations (mg/mL) of gel filtration purified
proteins were determined with a Nandrop 2000c (Thermo Scientific) at
280nm. Relative values were obtained using 2µL of protein.

Bradford Assays. Accurate concentrations (mg/mL) of proteins were
obtained through Bradford Assays compared with a standard curve plot.
Absorbance at 280nm were used to standardize concentrations of proteins
prior to experiments.
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Methyltransferase Assays. In vitro experiments using the MLL1 core
complex at 7µM were done over a time course to test for mono-, di-, and
tri-methylation activity as previously described4. 250µM of S-Adenosyl
Methionine (AdoMet), as well as 10µM of H3 (residues 1-20) peptide,
were added to the MWRAD complex and incubated at 15°C for 24 hours.
Aliquots were withdrawn at different time points and quenched using
0.5% Triflouroacetic acid (TFA). Each sample was then diluted 1:5 using
α-cyano-4-hydroxycinnamic acid, dried, and analyzed in reflectron mode
on the SUNY ESF MALDI-TOF mass spectrometer (Bruker Autoflex III).
Data obtained was the average of 100 shots/position at 5 different
positions chosen at random for each sample. Relative methylation values
were determined using mMass and plotted on a Microsft Excel spread
sheet to compare amounts of methylation over time.
Analytical Ultracentrifugation. Wild-type and mutant MLL1 were mixed
with various stoichiometric concentrations of WDR5 to determine if
binding was effected by a point mutation. 3mm two-sector charcoal filled
Epon centerpieces with quartz windows were assembled and samples were
loaded. The Beckman Coulter ProteomLab XL-A analytical
ultracentrifuge with absorbance optics was run at 10°C and 50,000RPM
using a 4 hole An-50 Ti rotor. The program scanned 0-min time intervals
for 300 scans and the data was analyzed using the continuous distribution
method c(s) in SEDFIT.
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GST Pulldown Assays. Wild-type and mutant GST-MLL1 proteins were
mixed with the WRAD complex to compare binding affinity of the MLL1
core complex after citrullination with PAD2. The proteins, assay buffer
(50mM Tris (pH 8.5), 0.2M NaCl, 5% Glycerol, and 10mM CaCl2), and
PAD2 were incubated at room temperature with glutathione beads over
several time points. Reactions were stagger started, so as to end at the
same time. Buffer washes were conducted to eliminate non-GST-bound
proteins. SDS-PAGE was used to separate proteins on a gel and determine
if WRAD successfully bound to GST-MLL1 in the presence of PAD2
over time.

Western Blotting. Novex NuPAGE gels were used to prepare
electrophoresis samples. However, instead of coomassie staining, bands
were transferred to a nitrocellulose membrane using electroblotting and
20x NuPAGE transfer buffer. The membrane was then verified using
Poncea S stain and the antibody was added. Lastly, the membrane was
probed using an antibody that detects the citrullinated MLL1 protein.
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Chapter III
Results

Expression and Purification of MLL1 Mutants
Human MLL1 3745-3969 mutants R3765L, R3746H, and R3771T were
expressed by inducing at OD600 1.0 using Isopropyl β-D-1 thiogalactopyranoside
(IPTG), which is a molecule that promotes transcription of the lac operon4.
Verification of induction can been seen on the left (Fig. 3) with an SDS-PAGE
gel.

Figure 3 shows:
Lane 1 = BioRad Standard Ladder (50kDa)
Lane 2 = Uninduced MLL1-GST Protein
Lane 3 = Induced MLL1-GST Protein
The induced lane shows a significant increase in
band intensity of protein between lane 2 and lane
3, which confirms induction.

Figure 3
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Harvested pellets were lysed through as microfluidizer with an EDTA Free
Protease Inhibitor Cocktail Tablet to avoid protein degradation. Purification of
MLL1 mutants proceeded through a GST affinity chromatography, dialysis for
buffer exchange, second GST affinity chromatography run, and finally gel
filtration chromatography. At the end of each column run, sample tubes were
chosen based off UV 280nm elution peaks when MLL1 came off the beads. These
tubes, as well as the input and flow through, were displayed on a SDS-PAGE gel
to analyze intensity of bands correlating to amount of protein and presence of
contaminants. Sample aliquots of protein were saved throughout the process of
purification for different experiments and stored at -80°C. GST fusion proteins
after GST run 1 were used for GST pulldown assays, cleaved GST run 2 proteins
were used for methylation assays, and gel filtration MLL1 was used for binding
assays using sedimentation velocity analytical ultracentrifugation. Band intensity
shown after gel filtration, though high in purity, were noticeably weaker and a
loss of protein was seen each time for all mutants and wild-type MLL1 proteins.
Destained coomassie gels can be seen below (Fig. 4, Fig. 5, Fig. 6) correlating to
GST1, GST2, and gel filtration.

Figure 4 (missing ladder) shows:
Lane 1 = Input
Lane 2 = Flowthrough
Lane 3 – 9 = Select MLL1
Protein Tubes
Figure 4
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Figure 5 shows:
Lane 1 = BioRad Standard
Ladder (25kDa)
Lane 2 = Dialysis Input
Lane 3 = Dialysis Output
Lane 4 – 15 = Select MLL1
Protein Tubes

Figure 5

Figure 6 shows:
Lane 1 = BioRad Standard Ladder (25kDa)
Lane 2 = Non-Concentrated Gel Filtration MLL1
Protein
Lane 3 = Concentrated Gel Filtration MLL Protein

Figure 6
MLL1 R3765L – Disruption of Complex Formation
Hypothesis: If the R3765L missense mutation in MLL1 causes loss-of-function
due to changes in physical properties of the amino acid from an arginine to a

14

leucine, then this would be indicative of R5340L doing the same in MLL2 due to
MLL1 and MLL2 being paralogs to each other in humans.
In order to analyze methylation activity (mono-, di-, and trimethylation activity), a
time course experiment and mass spectrometry were utilized to determine if
MLL1 and WRAD were binding based on methylation data compared to wildtype MLL1. Each methylation (CH3) results in a 15Da increase. Plotted data did
indicate a severe loss of dimethylation between MWTWRAD (Fig. 7a, Fig. 7b) and
MR3765LWRAD (Fig. 8a, Fig. 8b), while there was not a noticeable difference in
the level of monomethylation. This assay was repeated to validate the correlation
between mutation and disruption of binding.
Below are the results from the experiment conducted on August 2, 2012. Figures
7a (WT) and 8a (R3765L) are the plots from mMass (mono-, di-, tri- from left to
right), while Figures 7b (WT) and 8b (R3765L) are the same values plotted by
Microsoft Excel over the time period of 24 hours.
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Figure 7a

Figure 7b

Figure 8a
16

Figure 8b
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Once the loss of dimethylation was established when mutating R3765, analytical
ultracentrifugation was applied to better analyze complex formation. This real
time optical detection system using UV light absorption is able to distinguish

molecules based on shape and molecular mass. In wild-type conditions, the MLL1
and WDR5 complex sediments around 2.80, while separately MLL1 is ~1.80 and
WDR5 is ~2.37. Data obtained in July 2013 further supported the original
hypothesis that the MLL1 R3765L mutation negatively effects core complex
formation and, in doing so, greatly reduces, if not completely eliminates,
dimethylation. Fig. 9 (MWTWDR5) and 10 (MR3765LWDR5) show the plot from
SEDFIT (left) and values graphed on Microsoft Excel (right). A minor peak on
the left exists for both experiments and was attributed to either protein
degradation or contamination.

Figure 9
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Figure 10
MLL1 R3746H – A Neutral Mutation
Hypothesis: If the R3746H mutation was found in patient screens, but was not
correlated with KS. Then we therefore hypothesized that it would behave like
wild-type MLL1.
To test this hypothesis a similar MALDI-TOF and AUC experimentation set up
was used to test the similarity of wild-type and R3756H MLL1 proteins. Both of
which supported the initial hypothesis that was posited.
Figures 11a (WT) and 12a (R3746H) are peaks from mMass (mono-, di-,
trimethylation activity from left to right). Figures 11b (WT) and 12b (R3746H)
are plotted values on Microsoft Excel. Though a small variance exists, the
methylation trend is very similar.
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Figure 11a

Figure 11b

Figure 12a
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Figure 12b
Sedimentation experiments agreed with the MALDI-TOF results in that complex
was forming normally, despite this mutation. Figures 13 (WT) and 14 (R3746H)
show MLL1-WDR5 complex formation, however experimental data from MLL1
R3746H was determined to have concentrations that were not stoichiometric. An
excess of wild-type WDR5 led to the additional peak around 2.24.
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Figure 13

Figure 14
MLL1 R3771T – Presence in PAD2 Citrullination
Hypothesis: If the arginines at positions MLL1 3765 and 3771 f MLL1 are
citrullinated by PAD2, then either the R3771 is exposing R3765 to PAD2 or there
is no significance in this citrullination. Prior experimentation has already
determined the importance of both the Win motif and MLL1 R3765 in MWRAD
complex formation7.
Tests had been done before by Valerie Vought with PAD2 after MALDI-TOF
results showed an arginine 6 residues down from the highly conserved Win motif
arginine had been citrullinated in both MLL1. In addition, PAD2 displayed a high
affinity to MLL1 in comparison to the other members of the SET1 family and
PAD4.
To determine if PAD2 is a possible model for regulation of MLL1 core complex
assembly, MLL1 R3771T was tested for disruption of methylation. Figure 15
lends evidence towards a similarity with wild-type MLL1 methylation behavior.
22

Figure 15
A time course glutathione pulldown assay was created to determine if PAD2
citrullination negatively impacted core complex formation. Fusion GST-MLL1
WT and R3771T protein were used to bind with the glutathione beads.
Optimization tests were conducted to hone down the original conditions. Figure
19 shows a dramatic decrease in band intensity for WDR5 (top circle) and DPY30
(bottom circle) over the time period of 90 minutes. The left side being MLL1 WT
and right side being MLL1 R3771T in complex with WRAD.
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Figure 19
Repeat experiments showed similar results, which led to the goal of determining
if a difference existed between citrullination with and without the arginine at
position 3771 of MLL1. Due to the faint intensity of bands, analysis was unable to
draw a conclusive answer.
Initial steps were taken to utilize western blotting towards offering a better
method of quantification. Figure 20 shows a successful dot blot of an antibody
that selectively binds with MWRAD that has been citrullinated by PAD2. Faint
bands were seen with MWRAD and No CaCl2, which was attributed to
background binding. Controls of histone H3 (residues 1-20) + PAD2 showed
slight antibody binding, while the absence of CaCl2 showed no intensity, and the
enzyme, PAD2, alone did not bind with the antibody.
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Figure 20
Unfortunately western blotting results for MLL1 WT and MLL1 R3771T were
deemed inconclusive. Only two experimental attempts were made during the
academic school year. The first of which is seen below in Figure 20 (MLL1 WT,
coomassie) and Figure 21 (MLL1 WT, western blot). The data did show that there
was an inverse relationship between MLL1 core complex formation from the
glutathione pulldown and citrulline antibody binding. This supported the
hypothesis that PAD2 severely decreases complex formation through the
citrullination of R3765, and R3771 in the process. Both Figure 21 and 22 have the
same corresponding lanes. Lane 1 is the BioRad Standard Ladder, lane 2 is the
input, lane 3 through 10 are time points from zero to 1 hour, lane 11 is the WRAD
control, and lane 12 is the No CaCl2 control. As less complex shows up over time
on Figure 21, more citrulline antibody binds over time on Figure 22.
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Figure 21

Figure 22
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Chapter IV
Discussion and Conclusion

Positive Correlation of MLL1 Mutations and Dimethylation
MLL1 R3765 was determined to have a significant impact on MLL1 core
complex formation and normal dimethylation7. Results obtained from MALDITOF and AUC were repeated by Stephen Shinsky, a graduate student in Dr.
Cosgrove’s lab. Unlike other Kabuki Syndrome mutations in MLL2, this arginine
located in the Win motif led to an almost complete loss of dimethylation. Hence,
using a paralog of MLL2 R5340, the results supported the initial hypothesis that
the arginine located at 3765 is crucial in the interaction of MLL1 with WDR5.
PeptidylArginine Deiminase 2
Initial results were not conclusive, but support the hypothesis that MLL1 R3771
may play a role in citrullination of MLL1 R3765. A flaw exists when the SET1
family peptides were sent for MALDI-TOF analysis of the 1Da difference of
arginine and citrulline. MLL1 and MLL4, unlike MLL2, MLL3, SET1a, and
SET1b included both 3 extra amino acids before and after the central residues.
This could have aided in the stability of interaction with PAD2 and PAD4.
27

The arginine located at 3771 is not needed for the interaction of MLL1 with
WDR5 and is supported by crystal structures that show movement of R3771
lending further evidence that this amino acid does not interact with the surface of
WDR5.
Further research is needed to standardize the testing of SET1 family proteins and
PAD2/4 either by sending equal length peptide sequences or by using truncated
constructs in the GST pulldown assay. Shorter intervals of time may help in
quantifying MLL1 core complex formation. Repeating western blot assays under
optimized conditions will allow for more accurate quantification of PAD2
enzymatic activity over time and determine whether the R3771 plays a role in the
speed of R3765 citrullination.
Research Overview and Techniques learned from BCM460
These past three years of research have been eye opening in teaching me both
fundamental research techniques and developing a scientific mindset. Much of the
biochemistry that I learned while in Dr. Cosgrove’s lab has already aided me in
my undergraduate studies and has helped me obtain interviews for research
positions after graduation.
Many thanks go out to the members, both past and present, of the lab. I could not
have done this without your assistance. Though I wish more data could have been
collected and better experimental techniques could have been used, I believe
BCM460 has given me invaluable skills that will continue to be utilized in the
future.
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